Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The compan… Read more
Skye Bioscience, Inc. Common Stock (SKYE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.407x
Based on the latest financial reports, Skye Bioscience, Inc. Common Stock (SKYE) has a cash flow conversion efficiency ratio of -0.407x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.36 Million) by net assets ($32.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Skye Bioscience, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Skye Bioscience, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Skye Bioscience, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Skye Bioscience, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Plastiblends India Limited
NSE:PLASTIBLEN
|
-0.001x |
|
PRESSURE TECH.PLC LS -05
F:PRS
|
N/A |
|
Meshek Energy-Renewable Energies Ltd
TA:MSKE
|
0.010x |
|
CKX Lands Inc
NYSE MKT:CKX
|
0.013x |
|
NeoCore Technology Co., Ltd.
TWO:4131
|
-0.062x |
|
Philly Shipyard ASA
PINK:AKRRF
|
5.765x |
|
Silver Viper Minerals Corp
OTCQB:VIPRF
|
-0.218x |
|
Silver Bullet Mines Corp.
OTCQB:SBMCF
|
-1.155x |
Annual Cash Flow Conversion Efficiency for Skye Bioscience, Inc. Common Stock (2012–2024)
The table below shows the annual cash flow conversion efficiency of Skye Bioscience, Inc. Common Stock from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $68.15 Million | $-25.24 Million | -0.370x | -105.66% |
| 2023-12-31 | $-2.13 Million | $-13.95 Million | 6.545x | +54.48% |
| 2022-12-31 | $-3.01 Million | $-12.74 Million | 4.237x | +483.70% |
| 2021-12-31 | $5.86 Million | $-6.47 Million | -1.104x | +91.78% |
| 2020-12-31 | $450.79K | $-6.05 Million | -13.430x | -22.11% |
| 2019-12-31 | $548.06K | $-6.03 Million | -10.999x | -4440.97% |
| 2018-12-31 | $-15.56 Million | $-3.94 Million | 0.253x | -93.85% |
| 2017-12-31 | $-800.08K | $-3.30 Million | 4.122x | +68.34% |
| 2016-12-31 | $-1.45 Million | $-3.55 Million | 2.449x | +130.94% |
| 2015-12-31 | $471.00K | $-3.73 Million | -7.915x | -304.53% |
| 2014-12-31 | $-453.55K | $-1.76 Million | 3.870x | +873.40% |
| 2013-12-31 | $-36.46K | $-14.49K | 0.398x | +695.12% |
| 2012-12-31 | $38.56K | $1.93K | 0.050x | -- |